Treatment of multiple myeloma

Blood

Volumn 103, Issue 1, 2004, Pages 20-32

  Barlogie, Bart ^a   Shaughnessy, John ^b   Tricot, Guido ^b   Jacobson, Joth ^b   Zangari, Maurizio ^b   Anaissie, Elias ^b   Walker, Ron ^b   Crowley, John ^b  

^a UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ARSENIC TRIOXIDE; BISPHOSPHONIC ACID DERIVATIVE; BORTEZOMIB; BUSULFAN; CARMUSTINE; CD20 ANTIBODY; CISPLATIN; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOXORUBICIN; ENOXAPARIN; ETOPOSIDE; GLUCOCORTICOID; GRANULOCYTE COLONY STIMULATING FACTOR; IMATINIB; IMMUNOMODULATING AGENT; INTERFERON; INTERLEUKIN 6 ANTIBODY; LENALIDOMIDE; LOW MOLECULAR WEIGHT HEPARIN; MELPHALAN; MEPREDNISONE; NEW DRUG; PAMIDRONIC ACID; PREDNISONE; PROTEIN FARNESYLTRANSFERASE INHIBITOR; THALIDOMIDE; UNINDEXED DRUG; VINCRISTINE; ZOLEDRONIC ACID;

AMYLOIDOSIS; ANEMIA; ANTINEOPLASTIC ACTIVITY; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; AUTOLOGOUS PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; BONE MARROW SUPPRESSION; BONE MARROW TOXICITY; BRADYCARDIA; CANCER IMMUNOTHERAPY; CANCER SURVIVAL; CHROMOSOME ABERRATION; CLINICAL TRIAL; DOSE RESPONSE; DRUG EFFICACY; DRUG MEGADOSE; GENE EXPRESSION PROFILING; GERIATRIC PATIENT; GRAFT VERSUS HOST REACTION; GRAFT VERSUS MYELOMA EFFECT; HIGH RISK POPULATION; HUMAN; HYPERVISCOSITY SYNDROME; IMMUNE DEFICIENCY; IMMUNOGLOBULIN DEPOSITION; IMMUNOGLOBULIN DEPOSITION DISEASE; INFECTION; KIDNEY FAILURE; MAINTENANCE THERAPY; MONOCLONAL GAMMOPATHY OF UNDETERMINED SIGNIFICANCE; MONOCLONAL IMMUNOGLOBULINEMIA; MUCOSA INFLAMMATION; MULTIPLE MYELOMA; NEPHROTOXICITY; NEUROTOXICITY; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; PERIPHERAL NEUROPATHY; PLASMACYTOMA; PRIORITY JOURNAL; PROGNOSIS; REVIEW; SALVAGE THERAPY; THROMBOEMBOLISM; TREATMENT FAILURE; VACCINATION;

EID: 0346336804     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood-2003-04-1045     Document Type: Review

References (148)

1. Alexanian R, Dimopoulos M. The treatment of multiple myeloma. N Engl J Med. 1994;330:484-489.
2. Bataille R, Harousseau J. Multiple myeloma. N Engl J Med. 1 997;336:1657-1664.
3. Hallek M, Bergsagel P, Anderson K. Multiple myeloma: increasing evidence for a multistep transformation process. Blood. 1998;91:3-21.
4. Kuehl W, Bergsagel P. Multiple myeloma: evolving genetic events and host interactions. Nat Rev Cancer. 2002;2:175-187.
5. Barlogie B, Tricot G, Anaissie E. Thalidomide in the management of multiple myeloma. Semin Oncol. 2002;28:577-582.
6. Anderson KC. Targeted therapy for multiple myeloma. Semin Hematol. 2001;38:286-294.
7. Anderson K. Moving disease biology from the laboratory to the clinic. Semin Oncol. 2002;29:17-20.
8. Attal M, Harousseau JL, Stoppa AM, et al. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Francais du Myelome. N Engl J Med. 1996;335:91-97.
9. Yaccoby S, Epstein J. The proliferative potential of myeloma plasma cells manifest in the SCID-hu host. Blood. 1999;94:3576-3582.
10. Kyle R, Therneau T, Rajkumar S, et al. A long-term study of prognosis in monoclonal gammopathy of undetermined significance. N Engl J Med. 2002;346:564-569.
11. Drach J, Schuster J, Nowotny H, et al. Multiple myeloma: high incidence of chromosomal aneuploidy as detected by interphase fluorescence in situ hybridization. Cancer Res. 1995;55:3854-3859.
12. Avet-Loiseau H, Facon T, Daviet A, et al. 14q32 translocations and monosomy 13 observed in monoclonal gammopathy of undetermined significance delineate a multistep process for the oncogenesis of multiple myeloma. Intergroupe Francophone du Myelome. Cancer Res. 1999;59:4546-4550.
13. Zhan F, Hardin J, Kordsmeier B, et al. Global gene expression profiling of multiple myeloma, monoclonal gammopathy of undetermined significance and normal bone marrow plasma cells. Blood. 2002;99:1745-1757.
14. Wu K, Orme L, Shaughnessy J, Bumm K, Barlogie B, Moore M. Telomerase and telomere length in multiple myeloma: correlations with disease heterogeneity, cytogenetic status and overall survival. Blood. 2003;101:4982-4989.
15. Attal M, Harousseau JL, Facon T, et al. Double autologous transplantation improves survival of multiple myeloma patients: final analysis of a prospective randomized study of the "Intergroupe Francophone du Myelome" (IFM 94) [abstract]. Blood. 2002;100:7a.
16. Child J, Morgan G, Davies F, et al. High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma. N Engl J Med. 2003;348:1875-1883.
17. Singhal S, Mehta J, Desikan R, et al. Antitumor activity of thalidomide in refractory multiple myeloma. N Engl J Med. 1999;341:1565-1571.
18. Richardson PG, Schlossman RL, Weller E, et al. Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma. Blood. 2002;100:3063-3067.
19. Richardson P, Barlogie B, Berenson J, et al. A phase II multicenter study of the proteasome inhibitor bortezomib (Velcade™, formally PS-341) in multiple myeloma patients (pts) with relapsed/refractory disease [abstract]. Blood. 2002;100:104a.
20. Tricot G, Vesole DH, Jagannath S, Hilton J, Munshi N, Barlogie B. Graft-versus-myeloma effect; proof of principle. Blood. 1996;87:1196-1198.
21. Maloney D, Sahebi F, Stockerl-Goldstein K, et al. Combining an allogeneic graft-vs-myeloma effect with high-dose autologous stem cell rescue in the treatment of multiple myeloma [abstract]. Blood. 2001;99:434a.
22. Badros A, Barlogie B, Morris C, et al. High response rate in refractory and poor-risk multiple myeloma after allotransplantation using a nonmyeloablative conditioning regimen and donor lymphocyte infusions. Blood. 2001;97:2574-2579.
23. Bergsagel DE, Sprague CC, Austin C, Griffith KM. Evaluation of new chemotherapeutic agents in the treatment of multiple myeloma: IV. L-Phenylalanine mustard (NC-8806). Cancer Chemotherapy Rep. 1962;21:87.
24. Alexanian R, Haut A, Khan AU, et al. Treatment for multiple myeloma. Combination chemotherapy with different melphalan dose regimens. JAMA. 1969;208:1680-1685.
25. Myeloma Trialists' Collaborative Group. Combination chemotherapy versus melphalan plus prednisone as treatment for multiple myeloma: an overview of 6,633 patients from 27 randomized trials. J Clin Oncol. 1998;16:3832-3842.
26. McElwain TJ, Powles RL. High-dose intravenous melphalan for plasma-cell leukaemia and myeloma. Lancet. 1983;2:822-824.
27. Barlogie B, Hall R, Zander A, Dicke K, Alexanian R. High-dose melphalan with autologous bone marrow transplantation for multiple myeloma. Blood. 1986;67:1298-1301.
28. Barlogie B, Alexanian R, Dicke KA, et al. High-dose chemoradiotherapy and autologous bone marrow transplantation for resistant multiple myeloma. Blood. 1987;70:869-872.
29. Jagannath S, Vesole DH, Glenn L, Crowley J, Barlogie B. Low risk intensive therapy for multiple myeloma with combined autologous bone marrow and blood stem cell support. Blood. 1992;80:1666-1672.
30. Vesole DH, Barlogie B, Jagannath S, et al. High-dose therapy for refractory multiple myeloma: improved prognosis with better supportive care and double transplants. Blood. 1994;84:950-956.
31. Cunningham D, Paz-Ares L, Milan S, et al. High-dose melphalan and autologous bone marrow transplantation as consolidation in previously untreated myeloma. J Clin Oncol. 1994;12:759-763.
32. Fermand JP, Chevret S, Ravaud P, et al. High-dose chemoradiotherapy and autologous blood stem cell transplantation in multiple myeloma: results of a phase II trial involving 63 patients. Blood. 1993;82:2005-2009.
33. Attal M, Huguet F, Schlaifer D, et al. Intensive combined therapy for previously untreated aggressive myeloma. Blood. 1992;79:1130-1136.
34. Lenhoff S, Hjorth M, Holmberg E, et al. Impact on survival of high-dose therapy with autologous stem cell support in patients younger than 60 years with newly diagnosed multiple myeloma: a population-based study. Nordic Myeloma Study Group. Blood. 2000;95:7-11.
35. Powles R, Sirohi B, Singhal S, et al. 10-year survival in myeloma: a new endpoint for testing potentially curative strategies? [abstract] Blood. 2002;100:400a.
36. Sirohi B, Kulkarni S, Powles R. Some early phase II trials in previously untreated multiple myeloma: the Royal Marsden experience. Semin Hematol. 2001;38:209-218.
37. Bjorkstrand B. European Group for Blood and Marrow Transplantation Registry studies in multiple myeloma. Semin Hematol. 2001;38:219-225.
38. Govindarajan R, Jagannath S, Flick J, et al. Preceding standard therapy is the likely cause of MDS after autotransplants for multiple myeloma, BrJ Haematol. 1996;95:349-353.
39. Tricot G, Thertulien R, Jacobson J, et al. Treatment-related myelodysplastic syndromes (t-MDS) after autotransplants for multiple myeloma [abstract]. Blood. 2002;100:97a.
40. Tricot G, Jagannath S, Vesole D, et al. Peripheral blood stem cell transplants for multiple myeloma: identification of favorable variables for rapid engraftment in 225 patients. Blood. 1995;85:588596.
41. Morris C, Siegel E, Barlogie B, et al. Mobilization of CD34 + cells in elderly patients (≥ 70 years) with multiple myeloma: influence of age, prior therapy, platelet count and mobilization regimen. Br J Haematol. 2003;120:413-423.
42. Barlogie B, Smith L, Alexanian R. Effective treatment of advanced multiple myeloma refractory to alkylating agents. N Engl J Med. 1984;310:1353-1356.
43. Barlogie B, Jagannath S, Vesole D, et al. Superiority of tandem autologous transplantation over standard therapy for previously untreated multiple myeloma. Blood. 1997;89:789-793.
44. Alexanian R, Barlogie B, Dixon D. High-dose glucocorticoid treatment of resistant myeloma. Ann Intern Med. 1986;105;8-11.
45. Barlogie B, Vesole DH, Jagannath S., Salvage therapy for multiple myeloma: the University of Arkansas experience. Mayo Clin Proc. 1994;69:787-795.
46. Munshi N, Desikan R, Zangari M, et al. Chemoangiotherapy with DT-PACE for previously treated multiple myeloma (MM) [abstract]. Blood. 1999;94:540a.
47. Lee C-K, Barlogie B, Munshi N, et al. DTPACE: an effective, novel combination chemotherapy with thalidomide for previously treated patients with myeloma. J Clin Oncol. 2003;21:2732-2739.
48. Vesole DH, Tricot G, Jagannath S, et al. Autotransplants in multiple myeloma: what have we learned? Blood. 1996;88:838-847.
49. 2 melphalan as conditioning regimens for peripheral blood stem cell transplantation in patients with newly diagnosed multiple myeloma: final analysis of the Intergroupe Francophone du Myelome 9502 randomized trial. Blood. 2002;99:731-735.
50. Blade J, Sureda A, Ribera J, et al. High-dose therapy autotransplantation/intensification vs continued conventional chemotherapy in multiple myeloma patients responding to initial treatment chemotherapy. Results of a prospective randomized trial from the Spanish Cooperative Group [abstract]. PETHEMA. 2001;98:815a.
51. Cavo M, Tosi P, Zamagni E, et al. The Bologna 96 clinical trial of single versus double PBSC transplantation for previously untreated MM: results of an interim analysis. VIIIth International Myeloma Workshop Book. Banff, Canada 2001:29.
52. Segeren CN, Sonneveld P, van der Holt B, et al. Intensive versus double intensive therapy in previously untreated multiple myeloma: a prospective randomized phase III study in 450 patients. VIII International Myeloma Workshop Book. Banff, Canada; 2001:31.
53. Fermand JP, Marolleau JP, Alberti C. Single versus tandem high-dose therapy (HDT) supported with autologous blood stem cell (ABSC) transplantation using unselected or CD-34 enriched ABSC: preliminary results of a two by two design randomized trial in 230 young patients with multiple myeloma. VIII International Myeloma Workshop Book, Banff, Canada; 2001:147.
54. Hahn R, Wingard J, Anderson K, et al. The role of cytotoxic therapy with hematopoietic stem cell transplantation in the therapy of multiple myeloma: an evidence-based review. Biol Blood Marrow Transplant. 2003;9:4-37.
55. Greipp PR, Lust JA, O'Fallon WM, Katzmann JA, Witzig TE, Kyle RA. Plasma cell labeling index and beta 2-microglobulin predict survival independent of thymidine kinase and C-reactive protein in multiple myeloma. Blood. 1993;81:3382-3387.
56. Tricot G, Sawyer J, Jagannath S, et al. Poor prognosis in multiple myeloma is associated only with partial or complete deletions of chromosome 13 or abnormalities involving 11 q and not with other karyotype abnormalities. Blood. 1995;86:4250-4256.
57. Desikan R, Barlogie B, Sawyer J, et al. Results of high dose therapy for 1,000 patients with multiple myeloma: durable complete remissions and superior survival in the absence of chromosome 13 abnormalities. Blood. 2000;95:4008-4010.
58. Latreille J, Barlogie B, Dosik G, Johnston DA, Drewinko B, Alexanian R. Cellular DNA content as a marker of human multiple myeloma. Blood. 1980;55:403-408.
59. Facon T, Avet-Loiseau H, Guillerm G, et al. Intergroupe Francophone du Myelome. Chromosome 13 abnormalities identified by FISH analysis and serum beta2-microglobulin produce a powerful myeloma staging system for patients receiving high-dose therapy. Blood. 2001;97:1566-1571.
60. Shaughnessy J, Tian E, Sawyer J, et al. Prognostic impact of cytogenetic and interphase fluorescence in situ hybridization-defined chromosome 13 deletion in multiple myeloma: eady results of Total Therapy II. Br J Hematol. 2003;120:44-52.
61. Smadja NV, Bastard C, Brigaudeau C, Leroux D, Fruchart C. Groupe Francais de Cytogenetique Hematologique. Hypodiploidy is a major prognostic factor in multiple myeloma. Blood. 2001;98:2229-2238.
62. Shaughnessy J, Jacobson J, Sawyer J, et al. Continuous absence of cytogenetic abnormalities, especially of chromosome 13 and hypodiploidy, ensures long-term survival in multiple myeloma treated with Total Therapy I: interpretation in the context of global gene expression. Blood. 2003;101:3849-3856.
63. Attal M, Harousseau JL. Randomized trial experience of the Intergroup Francophone du Myelome: A prospective randomized trial of autologous bone-marrow transplantation and chemotherapy Semin Hematol. 2001;38:219-225.
64. Barlogie B, Desikan R, Eddlemon P, et al. Extended survival in advanced and refractory multiple myeloma after single-agent thalidomide: identification of prognostic factors in a phase 2 study of 169 patients. Blood. 2001;98:492-494.
65. Barlogie B, Zangari M, Spencer T, et al. Thalidomide in the management of multiple myeloma. Semin Hematol. 2001;38:250-259.
66. Kumar S, Gertz MA, Dispenzieri A, et al. Response rate, durability of response, and survival after thalidomide therapy for relapsed multiple myeloma. Mayo Clin Proc. 2003;78:34-39.
67. Zangari M, Anaissie E, Barlogie B, et al. Increased risk of deep-vein thrombosis in patients with multiple myeloma receiving thalidomide and chemotherapy. Blood. 2001;98:1614-1615.
68. Zangari M, Siegel E, Barlogie B, et al. Thrombogenic activity of doxorubicin in myeloma patients receiving thalidomide: implications for therapy. Blood. 2002;100:1168-1171.
69. Zangari M, Barlogie B, Anaissie E, et al. Abrogation of thrombogenic effect of the doxorubicin-thalidomide combination as part of Total Therapy II for newly diagnosed multiple myeloma by effective anti-coagulation with low molecular weight heparin [abstract]. Blood. 2002;100:398a.
70. Hideshima T, Anderson K. Molecular mechanisms of novel therapeutic approaches for multiple myeloma. Nat Rev Cancer. 2002;2:927-937.
71. Rajkumar SV, Hayman S, Gertz M, et al. Combination therapy with thalidomide plus dexamethasone for newly diagnosed myeloma. J Clin Oncol. 2002;21:4319-4323.
72. Weber D, Rankin K, Gavino M, Delasalle K, Alexanian R. Thalidomide alone or with dexamethasone for previously untreated multiple myeloma. J Clin Oncol. 2003;21:16-19.
73. Durie BG. Low-dose thalidomide in myeloma: efficacy and biologic significance. Semin Oncol. 2002;29:34-38.
74. Zangari M, Tricot G, Zeldis J, Eddlemon P, Saghafifar F, Barlogie B. Results of phase I study of CC-5013 for the treatment of multiple myeloma (MM) patients who relapse after high dose chemotherapy (HDCT) [abstract]. Blood. 2001;98:775a.
75. Adams J, Palombella V, Sausville E, et al. Proteasome inhibitors: a novel class of potent and effective antitumor agents. Cancer Res. 1999;59:2615-2622.
76. Hideshima T, Mitsiades C, Akiyama M, et al. Molecular mechanisms mediating antimyeloma activity of proteasome inhibitor PS-341. Blood. 2002;101:1530-1534.
77. Richardson P, Berenson J, Irwin D, et al. Phase II trial of PS-341, a novel proteasome inhibitor, alone or in combination with dexamethasone, in patients with multiple myeloma who have relapsed following front-line therapy and are refractory to their most recent therapy [abstract]. Blood. 2001;98:774a.
78. Yang HH, Vescio RA, Adams J, Schenkein D, Berenson JR. A phase I/II study of combination treatment with bortezomib and melphalan (Vc + M) in patients with relapsed or refractory multiple myeloma (MM) [abstract]. Proc Am Soc Clin Oncol. 2003;22:582a.
79. Ma M, Yang H, Parker K, et al. The proteasome inhibitor PS-341 markedly enhances sensitivity of multiple myeloma tumor cells to chemotherapeutic agents. Clin Cancer Res. 2003;9:1136-1144.
80. Orlowski R, Hall M, Voorhees P, et al. Phase I study of the proteasome inhibitor Bortezomib (PS-341, Velcade) in combination with pegylated liposomal doxorubicin (Doxil) in patients with refractory hematologic malignancies [abstract]. Blood. 2002;100:122a.
81. Zangari M, Barlogie B, Prather J, et al. Marked activity also in del 13 multiple myeloma (MM) of PS 341 (PS) and subsequent thalidomide (THAL) in a setting of resistance to post-autotranspiant salvage therapies [abstract]. Blood 2002;100:104a.
82. Munshi NC, Tricot G, Desikan R, et al. Clinical activity of arsenic trioxide for the treatment of multiple myeloma. Leukemia. 2002;16:1835-1837.
83. Hussein MA. Arsenic trioxide: a new immunomodulatory agent in the management of multiple myeloma. Med Oncol. 2001;18:239-242.
84. Bataille R, Barlogie B, Lu ZY, et al. Biologic effects of anti-interleukin-6 murine monoclonal antibody in advanced multiple myeloma. Blood. 1995;86:685-691.
85. Hussein M, Karam M, McLain D, et al. Biologic and clinical evaluation of Rituxan in the management of newly diagnosed multiple myeloma patients [abstract]. Blood. 1999;94:313a.
86. Hu L, Shi Y, Hsu JH, Gera J, Van Ness B, Lichtenstein A. Downstream effectors of oncogenic ras in multiple myeloma cells. Blood. 2003;101:3126-3235
87. Karp JE, Kaufmann SH, Adjei AA, Lancet JE, Wright JJ, End DW. Current status of clinical trials of farnesyltransferase inhibitors. Curr Opin Oncol. 2001;6:470-476.
88. Mackley P, Shain K, Dalton W, Alsina M. Farnesyl transferase inhibitor-R115777 decreases Akt phosphorylation in multiple myeloma cell lines and its apoptotic effects correlate with phosphoAKT expression levels [abstract]. Blood. 2002;100:810a.
89. Fonseca R, Oken MM, Greipp PR. Eastern Cooperative Oncology Group Myeloma Group. The t(4;14)(p16.3;q32) is strongly associated with chromosome 13 abnormalities in both multiple myeloma and monoclonal gammopathy of undetermined significance. Blood. 2001;98:1271-1272.
90. D'Amato R, Loughnan M, Flynn E, Folkman J. Thalidomide is an inhibitor of angiogenesis. Proc Natl Acad Sci U S A. 1994;91:4082-4085.
91. Shaughnessy J, Zhan F, Kordsmeier B, Randolph C, McCastlain K, Barlogie B. Gene expression profiling after short-term in vivo treatment identifies potential mechanisms of action of current drugs used to treat multiple myeloma [abstract]. Blood. 2002;100:781a.
92. Gharton F, Tura S, Ljungman P, et al. Allogeneic bone marrow transplantation in multiple myeloma. European Group for Bone Marrow Transplantation. N Engl J Med. 1991;325:1267-1273.
93. Bensinger W, Maloney D, Storb R. Allogeneic hematopoietic cell transplantation for multiple myeloma. Semin Hematol. 2001;38:243-249.
94. Giralt S, Thall P, Khourl I. et al. Melphalan and purine analog-containing preparative regimens: reduced-intensity conditioning for patients with hematologic malignancies undergoing allogeneic progenitor cell transplantation. Blood. 2001;97:631-637.
95. Badros A, Barlogie B, Siegel E, et al. Improved outcome of non-myeloablative allogeneic transplantation in multiple myeloma. J Clin Oncol. 2002;20:1295-1303.
96. Kroger N, Sayer HG, Schwerdtfeger R, et al. Unrelated stem cell transplantation in multiple myeloma after a reduced-intensity conditioning with pretransplantation antithymocyte globulin is highly effective with low transplantation-related mortality. Blood. 2002;100:3919-3924.
97. Lee CK, Badros A, Barlogie B, et al. Prognostic factors in allogeneic transplantation for patients with high-risk multiple myeloma after reduced intensity conditioning. Exp Hematol. 2003;31:73-80.
98. Mandelli F, Avvisati G, Amadori S, et al. Maintenance treatment with recombinant interferon alfa-2b in patients with multiple myeloma responding to conventional induction chemotherapy. N Engl J Med. 1990;322:1430-1434.
99. Ludwig FE. Interferon-alpha treatment in multiple myeloma: meta-analysis of 30 randomised trials among 3948 patients. Ann Oncol. 2000;11:1427-1436.
100. Yi Q, Osterborg A, Bergenbrant S, Mellstedt H, Holm G, Lefvert AK. Idiotype-reactive T-cell subsets and tumor load in monoclonal gammopathies. Blood. 1995;86:3043-3049.
101. Massaia M, Borrione P, Battaglio S, et al. Idiotype vaccination in human myeloma: generation of tumor-specific immune responses after high-dose chemotherapy. Blood. 1999;94:673-683.
102. Wen Y, Barlogie B, Yi Q. Idiotype-specific cytotoxic T lymphocytes in multiple myeloma: evidence for their capacity to lyse autologous primary tumor cells. Blood. 2001;97:1750-1755.
103. Yi Q, Desikan R, Barlogie B, Munshi N. Optimizing dendritic cell-based immunotherapy in multiple myeloma. Br J Hematol. 2002;117:297-305.
104. Wen YJ, Min R, Tricot G, Barlogie B, Yi Q. Tumor lysate-specific cytotoxic T lymphocytes in multiple myeloma: promising effector cells for immunotherapy. Blood. 2002;99:3280-3285.
105. van Baren N, Brasseur F, Godelaine D, et al. Genes encoding tumor-specific antigens are expressed in human myeloma cells. Blood. 1999;94:1156-1164.
106. Pellat-Deceunynck C, Mellerin MP, Labarriere N, et al. The cancer germ-line genes MAGE-1, MAGE-3 and PRAME are commonly expressed by human myeloma cells. Eur J Immunol. 2000;30:803-809.
107. Thurner B, Haendle I, Roder C, et al. Vaccination with mage-3A1 peptide-pulsed mature, monocyte-derived dendritic cells expands specific cytotoxic T cells and induces regression of some metastases in advanced stage IV melanoma. J Exp Med. 1999;190:1669-1678.
108. Pearse RN, Sordillo EM, Yaccoby S, et al. Multiple myeloma disrupts the TRANCE/osteoprotegerin cytokine axis to trigger bone destruction and promote tumor progression. Proc Natl Acad Sci USA. 2001;98:11581-11586.
109. Seidel C, Hjertner O, Abildgaard N, et al. Nordic Myeloma Study Group. Serum osteoprotegerin levels are reduced in patients with multiple myeloma with lytic bone disease. Blood. 2001;98:2269-2271.
110. Croucher PI, Shipman CM, Lippitt J, et al. Osteoprotegerin inhibits the development of osteolytic bone disease in multiple myeloma. Blood. 2001;98:3534-3540.
111. Tian E, Zhan F, Walker R, et al. The role of Wnt/beta-catenin signaling antagonist DKK1 in the development of osteolytic lesions in multiple myeloma. N Engl J Med. In press.
112. Berenson JR, Lichtenstein A, Porter L, et al. Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma. Myeloma Aredia Study Group. N Engl J Med. 1996;334:488-493.
113. Berenson JR, Rosen LS, Howell A, et al. Zoledronic acid reduces skeletal-related events in patients with osteolytic metastases. Cancer. 2001;91:1191-1200.
114. Yaccoby S, Pearse RN, Johnson CL, Barlogie B, Choi Y, Epstein J. Myeloma interacts with the bone marrow microenvironment to induce osteoclastogenesis and is dependent on osteoclast activity. Br J Hematol. 2002;116:278-290.
115. Berenson JR. Advances in the biology and treatment of myeloma bone disease. Semin Oncol. 2002;29:11-16.
116. Dhodapkar MV, Singh J, Mehta J, et al. Anti-myeloma activity of pamidronate in vivo. Br J Haematol. 1998;103:530-532.
117. Paget S. The distribution of secondary growths in cancer of the breast. Lancet. 1889:571-573.
118. Badros A, Barlogie B, Siegel E, et al. Results of autologous stem cell transplant in multiple myeloma patients with renal failure. Br J Hematol. 2001;114:822-829.
119. San Miguel JF, Lahuerta JJ, Garcia-Sanz R, et al. Are myeloma patients with renal failure candidates for autologous stem cell transplantation? Hematol J. 2000;1:28-36.
120. Siegel DS, Desikan KR, Mehta J, et al. Age is not a prognostic variable with autotransplants for multiple myeloma. Blood. 1999;93:51-54.
121. Badros A, Barlogie B, Siegel E, et al. Autologous stem cell transplantation in elderly multiple myeloma patients over the age of 70 years. Br J Hematol. 2001;114:600-607.
122. Palumbo A, Triolo S, Argentino C, et al. Dose-intensive melphalan with stem cell support (MEL100) is superior to standard treatment in elderly myeloma patients. Blood. 1999;94:1248-1253.
123. Lee C, Barlogie B, Zangari M, et al. Dialysis-dependent renal failure in patients with myeloma can be reversed by high-dose myeloablative therapy and autotransplant [abstract]. Blood. 2002;100:431a.
124. Dhodapkar M, Jagannath S, Vesole DH, et al. Treatment of AL-amyloidosis with dexamethasone plus alpha interferon. Leuk Lymphoma. 1997;27:351-356.
125. Dhodapkar MV, Jacobson J, Hussein M, et al. High dose dexamethasone with maintenance dexamethasone/alpha interferon leads to improved survival in patients with primary systemic amyloidosis [abstract]. Proc Am Soc Clin Oncol. 2003;22:566a.
126. Falk R, Comenzo R, Skinner M. The systemic amyloidosis. N Engl J Med. 1997;337:898-909.
127. Kumar S, Lacy M, Dispenzieri A, Grogan M, Gertz M. Peripheral blood stem cell transplantation for primary systemic amyloidosis with cardiac involvement [abstract]. Blood. 2002;100:180a.
128. Dimopoulos MA, Moulopoulos LA, Maniatis A, Alexanian R. Solitary plasmacytoma of bone and asymptomatic multiple myeloma. Blood. 2000;96:2037-2044.
129. Moulopoulos LA, Maris TG, Papanikolaou N, Panagi G, Vlahos L, Dimopoulos MA. Detection of malignant bone marrow involvement with dynamic contrast-enhanced magnetic resonance imaging. Ann Oncol. 2003;14:152-158.
130. Durie BG, Waxman AD, D'Agnolo A, Williams CM. Whole-body (18)F-FDG PET identifies highrisk myeloma. J Nucl Med. 2002;43:1457-1463.
131. Fourney DR, Schomer DF, Nader R, et al. Percutaneous vertebroplasty and kyphoplasty for painful vertebral body fractures in cancer patients. J Neurosurg. 2003;98:21-30.
132. Dudney S, Lieberman IH, Reinhardt MK, Hussein M. Kyphoplasty in the treatment of osteolytic vertebral compression fractures as a result of multiple myeloma. J Clin Oncol. 2002;9:2382-2387.
133. Evans A, Jensen M, Kip K, et al. Vertebral compression fractures: pain reduction and improvement in functional mobility after percutaneous polymethylmethacrylate vertebroplasty-retrospective report off 245 cases. Radiology. 2003;226:366-372.
134. Rajkumar SV, Dispenzieri A, Fonseca R, et al. Thalidomide for previously untreated indolent or smoldering multiple myeloma. Leukemia. 2001;15:1274-1276.
135. Weber DM, Dimopoulos M, Moulopoulos LA, et al. Prognostic features of asymptomatic multiple myeloma. Br J Hematol. 1997;97:810-814.
136. Silvestris F, Cafforio P, Tucci M, Dammacco F. Negative regulation of erythroblast maturation by Fas-L(+)/TRAIL(+) highly malignant plasma cells: a major pathogenetic mechanism of anemia in multiple myeloma. Blood. 2002;99:1305-1313.
137. Osterborg A, Brandberg Y, Molostova V, et al. Randomized, double-blind, placebo-controlled trial of recombinant human erythropoietin, epoetin beta, in hematologic malignancies. J Clin Oncol. 2002;20:2486-2494.
138. Nucci M, Anaissie E. Risks and epidemiology of infection after autologous hematopoietic slem cell transplantation. In: Bowden R, Ljungman P, Rubin R, eds. Transplant Infections, 2nd ed. Baltimore: Lippincott, Williams & Wilkins; 2004. In press.
139. Zent CS, Wilson CS, Tricot G, et al. Oligoclonal protein bands and Ig isotype switching in multiple myeloma treated with high-dose therapy and hematopoietic cell transplantation. Blood. 1998;91:3518-3523.
140. Weaver CH, Schwartzberg LS, Hainsworth J, et al. Treatment-related mortality in 1000 consecutive patients receiving high-dose chemotherapy and peripheral blood progenitor cell transplantation in community cancer centers. Bone Marrow Transplant. 1997;19:671-678.
141. Anaissie EJ, Stratton SL, Dignani MC, et al. Pathogenic molds (including Aspergillus species) in hospital water distribution systems: a 3-year prospective study and clinical implications for patients with hematologic malignancies. Blood. 2003;101:2542-2546.
142. Offidani M, Corvatta L, Olivieri A, et al. A predictive model of varicella-zoster virus infection after autologous peripheral blood progenitor cell transplantation. Clin Infect Dis. 2001;32:1414-1422.
143. Uzun O, Anaissie EJ. Antifungal prophylaxis in patients with hematological malignancies: a reap-praisal. Blood. 1995;86:2063-2072.
144. Junghanss C, Marr KA. Infectious risks and outcomes after stem cell transplantation: are nonmyeloablative transplants changing the picture? Curr Opin Infect Dis. 2002;15:347-353.
145. Berenson JR, Crowley JJ, Grogan TM, et al. Maintenance therapy with alternate-day prednisone improves survival in multiple myeloma patients. Blood. 2002;99:3163-3168.
146. Cunningham D, Powles R, Malpas J, et al. A randomized trial of maintenance interferon following high-dose chemotherapy in multiple myeloma: long-term follow-up results. Br J Hematol. 1998;102:495-502.
147. Stewart AK, Vescio R. Schiller G, et al. Purging of autologous peripheral-blood stem cells using CD34 selection does not improve overall or progression-free survival after high-dose chemotherapy for multiple myeloma: results of a multicenter randomized controlled trial. J Clin Oncol. 2001;19:3771-3779.
148. Salmon SE. Multiple myeloma: current perspectives on therapeutic management. Education Program of the 26th Congress of the International Society of Hematology. Singapore: 1996;5.